English Funding Nod For Lilly’s Diabetes GLP-1 Mounjaro, Roche’s Cancer MAb Columvi

Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.

Close up of diverse young people show thumbs up recommending good quality service, multiethnic clients or customers
• Source: Shutterstock/fizkes

England’s health technology assessment (HTA) body NICE has recommended Eli Lilly and Company’s Mounjaro (tirzepatide) for National Health Service use to treat patients with poorly controlled type 2 diabetes in 8 September draft guidance.

The positive reimbursement decision from NICE, which could see Mounjaro offered to up to 180,000 patients, reversed the HTA body’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet